NCT07762638Available不适用
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
3 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseFabry disease2024-513884-20-00Idorsia Pharmaceuticals Ltd.45
招募中
2 期
Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy2024-512700-18-00Sangamo Therapeutics Inc.1
Enrolling By Invitation
不适用
Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF)Fabry DiseaseNCT07560956Vastra Gotaland Region35
尚未招募
2 期
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)NCT07353437Fudan University334
尚未招募
不适用
Care Pathway for Patients With Fabry's Disease (Fabry-PATH)Fabry DiseaseNCT07485660University Hospital, Toulouse200